Grandfield & Dodd LLC Sells 1,246 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Grandfield & Dodd LLC lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 0.4% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 279,734 shares of the biopharmaceutical company’s stock after selling 1,246 shares during the quarter. Grandfield & Dodd LLC’s holdings in Gilead Sciences were worth $20,491,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of GILD. Hemenway Trust Co LLC bought a new stake in Gilead Sciences during the first quarter worth $487,000. SPC Financial Inc. raised its stake in shares of Gilead Sciences by 10.5% during the 1st quarter. SPC Financial Inc. now owns 4,212 shares of the biopharmaceutical company’s stock worth $309,000 after purchasing an additional 400 shares during the period. Noesis Capital Mangement Corp boosted its holdings in shares of Gilead Sciences by 4.9% in the 1st quarter. Noesis Capital Mangement Corp now owns 111,668 shares of the biopharmaceutical company’s stock worth $8,180,000 after buying an additional 5,223 shares during the last quarter. Affinity Investment Advisors LLC grew its position in Gilead Sciences by 13.9% during the first quarter. Affinity Investment Advisors LLC now owns 21,586 shares of the biopharmaceutical company’s stock valued at $1,581,000 after buying an additional 2,640 shares during the period. Finally, Catalina Capital Group LLC bought a new stake in Gilead Sciences in the first quarter worth about $204,000. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares in the company, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.29% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of a number of research reports. UBS Group reduced their target price on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Oppenheimer restated an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a research note on Friday, April 19th. TD Cowen cut their price target on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Friday, April 26th. Morgan Stanley lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, Barclays cut their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Twelve investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and an average target price of $84.00.

Check Out Our Latest Stock Report on Gilead Sciences

Gilead Sciences Price Performance

NASDAQ GILD traded up $1.22 during trading on Thursday, reaching $69.97. The company’s stock had a trading volume of 9,595,036 shares, compared to its average volume of 7,507,853. The stock has a market capitalization of $87.17 billion, a PE ratio of 194.36, a P/E/G ratio of 2.87 and a beta of 0.18. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.08 and a quick ratio of 0.94. The firm has a fifty day moving average of $66.32 and a 200 day moving average of $71.87. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion for the quarter, compared to analysts’ expectations of $6.36 billion. During the same period in the prior year, the business earned $1.37 earnings per share. Gilead Sciences’s revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 3.75 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were paid a $0.77 dividend. The ex-dividend date was Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a yield of 4.40%. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Further Reading

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.